Taken together, these findings suggest that Chk1 inhibitor-resistant Eμ-Myc/cRel−/− lymphomas develop resistance by down-regulating USP1, which results in Chk1 degradation, making it un-targetable (Figure 1). This evidence concerns the gene CHEK1 and lymphoma.